BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kechagias KS, Chorepsima S, Triarides NA, Falagas ME. Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence. Eur J Clin Microbiol Infect Dis 2020;39:1053-8. [DOI: 10.1007/s10096-019-03756-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol 2021;116:1124-47. [PMID: 34003176 DOI: 10.14309/ajg.0000000000001278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ; guideline committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021:S1198-743X(21)00568-1. [PMID: 34678515 DOI: 10.1016/j.cmi.2021.09.038] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wendt S, Ranft D, Rodloff AC, Lippmann N, Lübbert C. Switching From Ceftriaxone to Cefotaxime Significantly Contributes to Reducing the Burden of Clostridioides difficile infections. Open Forum Infect Dis 2020;7:ofaa312. [PMID: 33005693 DOI: 10.1093/ofid/ofaa312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kampouri E, Croxatto A, Prod'hom G, Guery B. Clostridioides difficile Infection, Still a Long Way to Go. J Clin Med 2021;10:389. [PMID: 33498428 DOI: 10.3390/jcm10030389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Camporeale A, Tellapragada C, Kornijenko J, Nord CE, Giske CG. In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden. Microbiol Spectr 2021;9:e0144021. [PMID: 34612686 DOI: 10.1128/Spectrum.01440-21] [Reference Citation Analysis]
6 Szabo BG, Duma L, Lenart KS, Kiss R, Vad E, Petrik BR, Ostorhazi E, Kadar B. Characteristics and predictors of treatment failure with intravenous tigecycline monotherapy among adult patients with severe Clostridioides (Clostridium) difficile infection: a single-centre observational cohort study. Diagn Microbiol Infect Dis 2021;99:115231. [PMID: 33099134 DOI: 10.1016/j.diagmicrobio.2020.115231] [Reference Citation Analysis]
7 Sholeh M, Krutova M, Forouzesh M, Mironov S, Sadeghifard N, Molaeipour L, Maleki A, Kouhsari E. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2020;9:158. [PMID: 32977835 DOI: 10.1186/s13756-020-00815-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
8 Honore PM, Mugisha A, Kugener L, Redant S, Attou R, Gallerani A, De Bels D. Clostridioides difficile infection in the critically ill: what kind of therapy for refractory cases. Crit Care 2020;24:142. [PMID: 32272951 DOI: 10.1186/s13054-020-02869-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Begum K, Bassères E, Miranda J, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Rashid T, Eyre DW, Wilcox MH, Alam MJ, Garey KW. In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile. Antimicrob Agents Chemother 2020;64:e00522-20. [PMID: 32513796 DOI: 10.1128/AAC.00522-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, Ghafouri Z, Maleki F. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis 2021. [PMID: 33403565 DOI: 10.1007/s10096-020-04121-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]